Prostate cancer is the most commonly diagnosed cancer in men in the western world and the second leading cause of cancer death [1] . Despite recent advances in early detection and new therapeutic approaches, the occurrence of metastatic disease due to androgen independence and resistance to existing treatments is common [2] [3] [4] [5] 
Introduction
Prostate cancer is the most commonly diagnosed cancer in men in the western world and the second leading cause of cancer death [1] . Despite recent advances in early detection and new therapeutic approaches, the occurrence of metastatic disease due to androgen independence and resistance to existing treatments is common [2] [3] [4] [5] . New [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Nevertheless, transduction of MSCs with adenoviral vectors is relatively inefficient compared with lentiviral gene transfer, as a result of the limited expression of the cellular coxsackie and adenovirus receptor on these cells [6, 11] [20, 21] .
. MSCs have greater potential to contribute to the population of stromal cells than fully differentiated fibroblasts. This allows the development of therapeutic strategies that are based on the local production of tumoricidal biological agents by MSCs transduced to express specific genes of interest. Demonstrating this capacity, MSCs have previously been shown to exert antitumour effects when transduced with adenoviruses expressing a variety of transgenes

. As a result of this inefficient transduction, the therapeutic transgene is diluted over time, limiting the use of adenoviral vectors to deliver gene therapy via MSCs. In contrast, lentivirus (LV)-based gene transfer compares favourably with other gene
Mesenchymal stem cells modified to express lentivirus TNF-␣
Tumour necrosis factor (TNF)-␣, an inflammatory cytokine, is cytotoxic to tumour cells, and also disrupts tumour blood vessels.
However, the clinical use of TNF-␣ as an antitumour drug is hampered by its severe systemic toxicity [22] . Another [24] .
In the present study, we describe the potential of using genetically modified MSCs that constitutively express TNF-␣-Tumstatin45-132 to inhibit the proliferation of prostate cancer cells in vitro and reduce xenograft tumour growth in vivo. We also examined the mechanisms of action of the approach.
Materials and methods
Cell culture
MSCs were isolated from bone marrow of 8-week-old Wistar rats and cultured as previously described [25, 26] 
Cloning and transfection
The signal peptide TNF-␣-Tumstatin45-132 (SPTT) fragment was generated by PCR amplification using pBV220-TNF-␣- [27] , and MSCs were transfected as described previously [28] . For 
Cell growth curves, ex vivo differentiation and DNA contents of transduced MSCs
The growth curve analysis and DNA quantitation of transduced MSCs were performed as described previously [29] . In addition, cultured transduced MSCs were tested for the ability to differentiate into osteogenic and adipogenic lineages using a previously described protocol [29] Fig. 1A-V (Fig. 1B) .
Cell proliferation assay
Endothelial tube formation assay
PCR and RT-PCR
Results
Efficient lentiviral transduction of MSCs
The MSCs were transduced with recombinant LV at a multiplicity of infection (MOI) of 25, and were found to efficiently express either the reporter gene (EGFP) or the SPTT target gene. The MSCs transduced with LV-EGFP showed evidence of a green fluorescent signal in almost all cells (Fig. 1A-I, II), and FACS analysis revealed that 96.8% of all cells expressed the transgene (Fig. 1A-III). To confirm the expression of the transgene, MSCs transduced with LV-EGFP and LV-SPTT were harvested, and protein lysates were prepared 72 hrs after transduction. Western blotting indicated that the SPTT protein was detectable in the cells transduced with LV-SPTT (Fig. 1A-IV). To determine the transduction efficiency of LV-SPTT in MSCs, the cells were harvested three days after transduction, fixed on slides, and subjected to immunohistochemistry using a human TNF-␣ antibody. The results indicated that the LV-EGFP-transduced MSCs were negative for the transgenic SPTT TNF-␣ protein (
Stem cell properties of MSCs are not affected by LV transduction or transgene expression
As shown in Fig. 1C , EGFP-MSCs and SPTT-MSCs exhibited virtually identical growth curves (Fig. 1C, upper panel) and cell cycle profiles (Fig. 1C, lower panel) (Fig. 2D) .
SPTT decreases the proliferation of prostate cancer cells in vitro
We then examined the effects of SPTT on prostate cancer cell proliferation. Treatment with the fusion resulted in anti-proliferative effects in both PC3 and LNCaP cells (Fig. 3A and B (Fig. 3C and D) . (Fig. 4C ). Fig. 5A . Fig. 5A and B) . (Fig. 6A, upper panels; 6B) . (Fig. 6A, middle panels; (Fig. 6A, lower panels; 6B ). (Fig. 6A and  B) , demonstrating that the effects on apoptosis and angiogenesis were specific to the SPTT-transduced MSCs. Fig. 7A) , In addition, we also found that the expression of Bax, a pro-apoptotic effector, increased in PC3 cells and tumours after treatment with SPTT-MSCs, whereas the expression of anti-apoptotic protein Bcl-2 decreased (Fig. 7A) . (Fig. 7B) .
Co-culture with SPTT-MSCs inhibits the growth of PC3 cells in vitro
We next examined the therapeutic potential of MSCs as cellular vehicles for production of SPTT using a co-culture system with PC3 cells under in vitro conditions. When the two cell lines were co-cultured, the SPTT-MSCs directly inhibited the growth of the malignant prostate cells (Fig. 4A), whereas co-culture with mocktransduced MSCs did not have this inhibitory effect.
Inhibition of angiogenesis by SPTT in vitro
The ability of SPTT to block angiogenesis in vitro was evaluated using the endothelial tube formation assay. When HUVEC cells are cultured on matrigel, they rapidly align and form hollow tube-like structures. Compared to cells cultured with control media (Fig. 4B-I)
Fig. 1 LV-transduced MSCs efficiently express human TNF-␣-Tumstatin45-132 fusion protein and maintain their stem cell properties. (A) The morphology, transduction efficiency examination of LV-transduced MSCs. LV-EGFP-transduced MSCs (I, bright field; II, fluorescence field). FACS analysis showed that almost all of the MSCs expressed EGFP (III). The 66 kD SPTT protein was detectable by Western blot analysis in cell lysates from SPTTMSCs (IV). Immunohistochemical staining revealed that whereas the mock-transduced MSCs were not stained for human TNF-␣ (V), but the SPTTMSCs exhibited positive staining (VI). (B) RT-PCR showed that SPTT was only expressed in the tranduced SPTT-MSCs. Ubiquitin promoter gene was detectable in both LV-EGFP and LV-SPTT-transduced MSCs. Oct-4 was expressed in all of the cells (MSCs, EGFP-MSCs and SPTT-MSCs). (C) LV-transduced MSCs exhibited a virtually identical growth curve compared to that of untransduced parental cells (upper panel). Cell cycle analysis demonstrated that there were similar DNA contents between non-transduced and LV-transduced MSCs (lower panel). These results are representative of the average of three experiments performed in triplicates. (D) The transduced MSCs (LV-EGFP and LV-SPTT) could differentiate into either osteocyte or adipocyte lineages after induction, as indicated by ALP and oil red staining. and conditioned media from EGFP-MSCs (Fig. 4B-II), the conditioned media of SPTT-MSCs significantly inhibited endothelial tube formation (Fig. 4B-III). The extent of tube formation after treatment with conditioned media from SPTT-MSCs was less than half of that observed in the group treated with media from EGFPMSCs
LV-SPTT-transduced MSCs inhibit the growth of PC3 xenografts in mice
Given its potent in vitro activity, we wanted to know whether MSCs transduced with LV-SPTT would also have antitumour activity in vivo. Mice bearing PC3 xenograft tumours were injected peritumorally with parental (non-transduced) MSCs, EGFP-MSCs or SPTT-MSCs. Representative tumours harvested at the conclusion of the experiment are shown in
Although the tumour mass was markedly smaller in the mice treated with SPTT-MSCs, the LV-EGFPtransduced MSCs did not lead to any significant difference in tumour size or weight compared to the mice treated with PBS or the control MSCs (
The differential effects of the control MSCs and SPTT-MSCs were further illustrated by the tumour growth curves (Fig. 5C). All of the tumours in the animals treated with PBS, non-transduced MSCs, or LV-EGFP-transduced MSCs grew to about six times their original size. In contrast, the tumours treated with the LV-SPTT-transduced MSCs only grew by a factor of 2.0.
LV-SPTT-transduced MSCs decrease tumour cell proliferation, promote apoptosis and decrease tumour vascularity
Immunohistochemical examination of the expression of PCNA revealed that the number of proliferating tumour cells was significantly lower in the tumours from mice in the LV-SPTT-transduced MSCs group compared with the groups treated with PBS, MSCs © 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 SPTT expression and its in vitro effects on the growth of prostate cancer and endothelial cells. (A) The level of SPTT protein in the culture supernatants of SPTT-MSCs increased with transduction time, reaching a peak at 3 to 4 days after transduction. (B) The SPTT protein from culture supernatants of SPTT-MSCs inhibited the growth of PC3 cells in vitro. Human TNF-␣ (5 g/ml) was used as a positive control. (C) The SPTT protein from culture supernatants of SPTT-MSCs inhibited the growth of LNCaP cells in vitro. (D) The SPTT protein in culture supernatants from SPTT-MSCs inhibited the growth of ECV304 cells in vitro. Human TNF-␣ (5 g/ml) was used as a negative control. The data are presented as means Ϯ S.D. of triplicate experiments (*P Ͻ 0.05 compared to mock-transduced MSCs). or LV-EGFP-transduced MSCs
Additionally, TUNEL staining demonstrated that there was an increase in apoptosis in the tumour cells in mice following treatment with LV-SPTT-transduced MSCs compared with the cells in mice treated with PBS, control MSCs, or LV-EGFP-transduced MSCs
6B). Immunohistochemical analysis of CD31, a marker for blood vessels, revealed that there were also significantly lower blood vessel counts in the tumours of mice treated with SPTT-MSCs compared with those treated with PBS, control MSCs, or LV-EGFP MSCs
There were no significant differences in the apoptosis or vascularity of tumours in mice treated with MSCs expressing EGFP compared with those treated with PBS or control MSCs
Activation and induction of apoptosis-related proteins by SPTT treatment
To investigate the mechanisms responsible for the activity of LV-SPTT-transduced MSCs against prostate cancer, the prostate cancer cells and tumours were lysed and proteins were collected. Western blotting analysis of tumour cells and tissues showed that treatment with SPTT-MSCs led to increased cleavage of caspases-8 and -3 (
SPTT-MSCs reduce the phosphylation of ERK-1/2 and Akt, but do not affect NF-B or JNK
The results of Western blotting analysis confirmed that the phosphorylation of ERK-1/2 and Akt was decreased in tumour cells and xenografts treated with SPTT-MSCs (Fig. 7A). Because TNF-␣ activates NF-B signalling as well as apoptosis, it is possible that it may elicit a pro-survival response that might counteract its increase in cell death. To investigate this possibility, we analysed the response of PC3 cells to the SPTT fusion protein with regard to nuclear factor κ-light-chain enhancer of activated B cells (NF-B) and c-Jun N-terminal kinase (JNK) signalling. As shown in Fig. 7B, the expression of the NF-B protein and the phosphorylation of inhibitor of nuclear factor κ-B kinase (IKK)-␤ and I-B␣ did not change, nor was there any inhibition of JNK activity
Discussion
The use of recombinant proteins for the treatment of cancer is often limited by their short half-life or excessive toxicity. More effective therapeutic strategies that can provide sustained antitumour effects, and that can preferentially deliver the therapeutic agent to the tumour will increase patient survival [31] . MSCs have been considered promising candidates for the expression of therapeutic proteins by gene transfer because their ability to be transduced with viral and non-viral vectors [32] . Studies 
(demonstrated by its inhibition of ECV304 cell proliferation). This indicates that the fusion of TNF-␣ and
